Form 4: Adaptive Biotechnologies COO Sells Shares
Insider Transaction (Form 4)
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, sold 35,643 shares of common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 11,881 Common Stock at $12.14 ($144,235) on October 1, 2026; holds 389,683 after (Direct).
- Open-market sale: disposed of 6,081 Common Stock at $27.57 ($167,653) on October 1, 2026; holds 383,602 after (Direct).
- Open-market sale: disposed of 5,800 Common Stock at $28.56 ($165,648) on October 1, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: acquired 11,881 Common Stock at $12.14 ($144,235) on October 2, 2026; holds 389,683 after (Direct).
- Open-market sale: disposed of 11,881 Common Stock at $28.13 ($334,213) on October 2, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: acquired 11,881 Common Stock at $12.14 ($144,235) on October 5, 2026; holds 389,683 after (Direct).
- Open-market sale: disposed of 6,699 Common Stock at $28.82 ($193,065) on October 5, 2026; holds 382,984 after (Direct).
- Open-market sale: disposed of 5,182 Common Stock at $29.67 ($153,750) on October 5, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: disposed of 11,881 Stock Option (right to buy) on October 1, 2026; holds 367,896 after (Direct).
- Option exercise/conversion: disposed of 11,881 Stock Option (right to buy) on October 2, 2026; holds 356,015 after (Direct).
- Option exercise/conversion: disposed of 11,881 Stock Option (right to buy) on October 5, 2026; holds 344,134 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,014,329 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Julie Rubinstein — Officer (President and COO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 11,881 | $12 | $144.2K | 389,683 |
| 2026-10-01 | Open-market sale | Common Stock | 6,081 | $28 | $167.7K | 383,602 |
| 2026-10-01 | Open-market sale | Common Stock | 5,800 | $29 | $165.6K | 377,802 |
| 2026-10-02 | Option exercise/conversion | Common Stock | 11,881 | $12 | $144.2K | 389,683 |
| 2026-10-02 | Open-market sale | Common Stock | 11,881 | $28 | $334.2K | 377,802 |
| 2026-10-05 | Option exercise/conversion | Common Stock | 11,881 | $12 | $144.2K | 389,683 |
| 2026-10-05 | Open-market sale | Common Stock | 6,699 | $29 | $193.1K | 382,984 |
| 2026-10-05 | Open-market sale | Common Stock | 5,182 | $30 | $153.7K | 377,802 |
| 2026-10-01 | Option exercise/conversion | Stock Option (right to buy) | 11,881 | — | — | 367,896 |
| 2026-10-02 | Option exercise/conversion | Stock Option (right to buy) | 11,881 | — | — | 356,015 |
| 2026-10-05 | Option exercise/conversion | Stock Option (right to buy) | 11,881 | — | — | 344,134 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (11,881 shares) |
| 2026-10-01 | Open-market sale (6,081 shares) |
| 2026-10-01 | Open-market sale (5,800 shares) |
| 2026-10-02 | Option exercise/conversion (11,881 shares) |
| 2026-10-02 | Open-market sale (11,881 shares) |
| 2026-10-05 | Option exercise/conversion (11,881 shares) |
| 2026-10-05 | Open-market sale (6,699 shares) |
| 2026-10-05 | Open-market sale (5,182 shares) |
| 2026-10-01 | Option exercise/conversion (11,881 shares) |
| 2026-10-02 | Option exercise/conversion (11,881 shares) |
| 2026-10-05 | Option exercise/conversion (11,881 shares) |
Keywords
insider transaction, Form 4, ADPT, Adaptive Biotechnologies Corp, bearish, Julie Rubinstein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.